Status of HPV vaccine introduction and barriers to country uptake

K.E Gallagher,D.S Lamontagne,D Watson-Jones

doi:10.1016/j.vaccine.2018.02.003

K.E Gallagher, D.S Lamontagne + Show 1 more

Open Access

https://doi.org/10.1016/j.vaccine.2018.02.003

Copy DOI

Journal: Vaccine	Publication Date: Mar 23, 2018
Citations: 160	License type: cc-by

Affiliation: London School of Hygiene & Tropical Medicine

Abstract

During the last 12 years, over 80 countries have introduced national HPV vaccination programs. The majority of these countries are high or upper-middle income countries. The barriers to HPV vaccine introduction remain greatest in those countries with the highest burden of cervical cancer and the most need for vaccination. Innovation and global leadership is required to increase and sustain introductions in low income and lower-middle income countries.

Highlights

During the last 12 years, over 80 countries have introduced national human papillomavirus (HPV) vaccination programs
By the end of 2008, a quarter of high-income and upper-middleincome countries (HIC/UMIC) had introduced national HPV vaccination programs but there had been no national introductions in low- and lower-middle-income countries (LIC/LMIC)
Despite vaccine licensure in 2006 and rapid uptake by some HIC, funding and support for introductions in LIC/LMIC only became available to the poorest countries in 2013 through Gavi and even it was in practice restricted to demonstration projects until countries accrued some experience in delivering a new vaccine to young adolescents

Summary

The status of HPV vaccine introduction

Since first licensure of human papillomavirus (HPV) vaccines in 2006, the HPV vaccines (bivalent, quadrivalent and 9-valent) have proven to be safe, highly immunogenic and to induce strong direct and indirect protection against HPV and its sequelae [1,2,3,4,5]. Despite vaccine licensure in 2006 and rapid uptake by some HIC, funding and support for introductions in LIC/LMIC only became available to the poorest countries in 2013 through Gavi and even it was in practice restricted to demonstration projects until countries accrued some experience in delivering a new vaccine to young adolescents. For most countries, this meant that funding for national introductions was available from 2015, after the first two-year demonstration projects were completed. The 12 national introductions among LIC/LMIC within two years from funding and affordable vaccine really being available (2015–2016) are encouraging [10]

Programmatic

Residual barriers to delivery now

Findings

Conclusion